Last updated: February 14, 2026
Overview of the Product
NDC 71205-0885 corresponds to a biosimilar approved for the treatment of inflammatory conditions. Its primary indication is rheumatoid arthritis, psoriatic arthritis, and other autoimmune diseases, matching the reference biologic's therapeutic profile.
Market Size and Growth Drivers
The biologic and biosimilar markets are expanding rapidly. According to IQVIA data, the U.S. biologic market reached $165 billion in 2022, with a Compound Annual Growth Rate (CAGR) of approximately 11% over the past five years. Biosimilars account for roughly 15% of the biologic market but are gaining share due to patent expirations, regulatory pathways, and affordability pressures.
Key factors influencing market growth for this biosimilar include:
- Patent expiry of reference biologic in 2019.
- Increasing adoption of biosimilars driven by payer preference.
- Demand for cost-saving alternatives amidst rising healthcare costs.
Competitive Landscape
The biosimilar space targeting indications like rheumatoid arthritis includes:
- Etanercept biosimilars (e.g., Erelzi, Renflexis)
- Adalimumab biosimilars (e.g., Amjevita, Hyrimoz)
- The product is among the newer entrants, with limited direct competition yet.
Brand biologics typically retail at $50,000–$60,000 annually per patient. Biosimilar entries often price at 15–35% lower.
Pricing Benchmarking
Based on existing biosimilar launches, initial list prices tend to be:
- 15–20% below the reference biologic
- Ranges from $40,000–$50,000 per patient annually
Post-launch, prices often decrease by 10–20% within the first two years.
Price Projection Timeline
| Year |
Estimated Price Range |
Assumptions |
| 2023 |
$45,000–$50,000 |
Launch year; initial pricing aligned with biosimilar norms |
| 2024 |
$40,500–$45,000 |
Slight discounts as market stabilizes |
| 2025 |
$36,000–$40,500 |
Price reductions driven by payer negotiations and increased biosimilar penetration |
| 2026 |
$32,000–$36,000 |
Further competition consolidates discounts |
Market Penetration Potential
Biosimilars historically capture 30–50% of the biologic market within five years post-launch. The rate depends on:
- Discount levels
- Physician and patient acceptance
- Payer rebates
Given the product's clinical profile, an adoption rate of 30%–40% within five years is reasonable, potentially impacting pricing further.
Regulatory and Reimbursement Considerations
The biosimilar has received FDA approval with a pathway favorable to biosimilar market entry:
- Interchangeability status has not yet been granted but could influence market share.
- Medicaid and Medicare reimbursements often favor lower-cost biosimilars.
- Payer rebates and contracting strategies can reduce net prices by 10–25%.
Financial Impact and Revenue Projections
Assuming:
- 50,000 treated patients in the U.S. (based on target indication prevalence)
- Initial market share: 5% in Year 1, growing to 25% by Year 5
- Average price decline as outlined
Estimated gross sales:
- Year 1: ~$112.5 million
- Year 2: ~$168.75 million
- Year 3: ~$240 million
- Year 4: ~$313 million
- Year 5: ~$375 million
Gross revenues may be reduced by 15–25% after rebates, leading to net sales of approximately $85–$314 million over five years.
Summary
The biosimilar corresponding to NDC 71205-0885 is positioned to capture a significant share of the autoimmune biologic market, with initial list prices around $45,000 per patient annually. Prices are projected to decline 10–20% annually during the first years post-launch, influenced by competitive dynamics, payer negotiations, and clinical adoption.
Key Takeaways
- The drug enters a rapidly growing biosimilar market with significant potential.
- Price points initially align with biosimilar norms, around $45,000 per patient annually.
- Prices are expected to decline by up to 20% annually in the first few years.
- Market share depends on payer strategies, physician acceptance, and regulatory factors.
- Total sales could reach approximately $300 million annually within five years.
FAQs
1. How does the pricing of this biosimilar compare to reference biologics?
It is approximately 15–20% lower, typically around $45,000 per patient annually, compared to $50,000–$60,000 for reference biologics.
2. What factors could influence price declines post-launch?
Market competition, payer rebates, negotiated discounts, and increasing biosimilar adoption can drive prices down by 10–20% annually.
3. What is the expected timeline for market penetration?
A 30–40% market share within five years is typical for biosimilars in auto-immune indications, contingent on acceptance and reimbursement strategies.
4. How will regulatory status affect pricing and market share?
Interchangeability designation, if granted, can accelerate adoption and pricing power, possibly maintaining higher prices longer.
5. What are the key risks to revenue forecasts?
Delays in market entry, regulatory challenges, limited physician and payer acceptance, or aggressive price competition could reduce projected sales.
References
[1] IQVIA. "The Annual Review of the Biopharma Market," 2022.
[2] FDA. "Biosimilar Approval Pathways," 2022.
[3] EvaluatePharma. "Global Biosimilar Market Data," 2022.
